Trial
NCT03588936
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Medical College of Wisconsin
Collaborators
—
Condition
Acute Leukemia
Intervention
Nivolumab (.25 mg/kg)
Why stopped
Poor accrual and loss of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-11